Publisher Correction: Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo.

The Acknowledgements section in the original version of this Article was incomplete. It now reads: “The surveys in the Democratic Republic of the Congo were generously supported by the American People through the United States Agency for International Development (USAID) via its ENVISION project (cooperative agreement number OAA-A-11-00048) and Act to End NTDs | East program (cooperative agreement No. 7200AA18CA00040), implemented by RTI International. The surveys and activities in the Togolese Republic were generously supported by the American People through the USAID via its End Neglected Tropical Diseases in Africa project (cooperative agreement number AID-OAA-A-10-00050), managed by FHI 360. Laboratory work at CDC was funded through an interagency agreement with USAID. Disclaimer: The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated. The authors declare no competing interests.

Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo.

Trachoma, caused by repeated ocular infection with Chlamydia trachomatis (Ct), is targeted for elimination as a public health problem. Serological testing for antibodies is promising for surveillance; determining useful thresholds will require collection of serological data from settings with different prevalence of the indicator trachomatous inflammation-follicular (TF). Dried blood spots were collected during trachoma mapping in two districts each of Togo and Democratic Republic of the Congo. Anti-Ct antibodies were detected by multiplex bead assay (MBA) and three different lateral flow assays (LFA) and seroprevalence and seroconversion rate (SCR) were determined. By most tests, the district with > 5% TF (the elimination threshold) had five-sixfold higher seroprevalence and tenfold higher SCR than districts with < 5% TF. The agreement between LFA and MBA was improved using a black latex developing reagent. These data show optimization of antibody tests against Ct to better differentiate districts above or below trachoma elimination thresholds